Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Martin Feuring & Joanne van Ryn. (2016) The discovery of dabigatran etexilate for the treatment of venous thrombosis. Expert Opinion on Drug Discovery 11:7, pages 717-731.
Read now
Read now
Daniel Caldeira, Joaquim J. Ferreira, Fausto J. Pinto & João Costa. (2016) Safety of non-vitamin K antagonist oral anticoagulants - coronary risks. Expert Opinion on Drug Safety 15:6, pages 731-740.
Read now
Read now
Sebastian M Schellong. (2015) Dabigatran for the treatment of venous thromboembolism. Expert Review of Hematology 8:4, pages 413-425.
Read now
Read now
Daniele Pontillo & Nicolino Patruno. (2014) Dabigatran and myocardial infarction: a foggy scenario. Vascular Health and Risk Management 10, pages 45-48.
Read now
Read now
Richard Brown, Gregory YH Lip & Pilar Gallego. (2014)
Dabigatran etexilate for venous thromboembolism: a safety evaluation. Expert Opinion on Drug Safety 13:5, pages 639-647.
Read now
Read now
Articles from other publishers (24)
Victor D Torres Roldan, Oscar J Ponce, Meritxell Urtecho, Gabriel F Torres, Tereza Belluzzo, Victor Montori, Carolina Liu, Francisco Barrera, Alejandro Diaz, Larry Prokop, Gordon Guyatt & Victor M Montori. (2021) Understanding treatment-subgroup effect in primary and secondary prevention of cardiovascular disease: An exploration using meta-analyses of individual patient data. Journal of Clinical Epidemiology 139, pages 160-166.
Crossref
Crossref
Harsukh Benipal, Anne Holbrook, J. Michael Paterson, James Douketis, Gary Foster & Lehana Thabane. (2020) Predictors of oral anticoagulant-associated adverse events in seniors transitioning from hospital to home: a retrospective cohort study protocol. BMJ Open 10:9, pages e036537.
Crossref
Crossref
Vivencio Barrios, David Vivas, Felipe Atienza Fernández, Miguel Ángel Arias, Raquel Diaz Simón, Aquilino Sánchez Purificación & Gonzalo Barón-Esquivias. (2020) Paciente con alto riesgo cardiovascular y fibrilación auricular: papel del rivaroxabán. Revista Española de Cardiología Suplementos 20, pages 30-38.
Crossref
Crossref
Eduardo Alegría Ezquerra, Rosa Agra Bermejo, Luis Javier Alonso Perez, Miguel Ángel Fernández Fernández, Jose Manuel Vázquez Rodríguez, Óscar Díaz Castro, Marisol Bravo Amaro, Ramón Ríos Vázquez & Julio Martí-Almor. (2020) Fibrilación auricular y cardiopatía isquémica: más allá de la prevención del ictus. Revista Española de Cardiología Suplementos 20, pages 11-20.
Crossref
Crossref
Alina Scridon, Alina Mărginean, Adina Huțanu, Laura Chinezu, Dan Gheban, Marcel Perian, Adriana Vântu, Doina Gherțescu, Paul C. Fișcă, Rǎzvan C. Șerban, Philippe Chevalier & Dan Dobreanu. (2019) Vascular protease‐activated receptor 4 upregulation, increased platelet aggregation, and coronary lipid deposits induced by long‐term dabigatran administration – results from a diabetes animal model. Journal of Thrombosis and Haemostasis 17:3, pages 538-550.
Crossref
Crossref
Angelika Batta, BhupinderS Kalra & Raj Khirasaria. (2019) Critical Issues and Recent Advances in Anticoagulant Therapy: A Review. Neurology India 67:5, pages 1200.
Crossref
Crossref
M J Pekka Raatikainen, Tero Penttilä, Pasi Korhonen, Juha Mehtälä, Riitta Lassila & Mika Lehto. (2018) The quality of warfarin therapy and CHA2DS2-VASc score associate with the incidence of myocardial infarction and cardiovascular outcome in patients with atrial fibrillation: data from the nationwide FinWAF Registry. European Heart Journal - Cardiovascular Pharmacotherapy 4:4, pages 211-219.
Crossref
Crossref
Rajashree RanaTianfang HuangGeorgios KoukosElizabeth K. FletcherSusan E. TurnerAndrew ShearerPaul A. GurbelJeffrey J. RadeCarey D. KimmelstielKevin P. BlidenLidija CovicAthan Kuliopulos. (2018) Noncanonical Matrix Metalloprotease 1–Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 38:6, pages 1368-1380.
Crossref
Crossref
Farhan Shahid, Daniele Pastori, Francesco Violi & Gregory Y.H. Lip. (2018) Prognostic and therapeutic implications of vascular disease in patients with atrial fibrillation. Pharmacological Research 132, pages 149-159.
Crossref
Crossref
Renske H. Olie, Paola E.J. van der Meijden & Hugo ten Cate. (2018) The coagulation system in atherothrombosis: Implications for new therapeutic strategies. Research and Practice in Thrombosis and Haemostasis 2:2, pages 188-198.
Crossref
Crossref
Leo M. Stolk, Frank de Vries, Chiel Ebbelaar, Anthonius de Boer, Tom Schalekamp, Patrick Souverein, Arina ten Cate-Hoek & Andrea M. Burden. (2017) Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants. British Journal of Clinical Pharmacology 83:8, pages 1835-1843.
Crossref
Crossref
Zachary Stacy & Sara Richter. (2016) Practical Considerations for the Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation. Clinical and Applied Thrombosis/Hemostasis 23:1, pages 5-19.
Crossref
Crossref
Lee Joseph & John R. Bartholomew. (2016) Managing Extended Oral Anticoagulation After Unprovoked Venous Thromboembolism. Journal of Cardiovascular Pharmacology and Therapeutics 22:1, pages 28-39.
Crossref
Crossref
Daniele Pastori, Pasquale Pignatelli, Mirella Saliola, Roberto Carnevale, Tommasa Vicario, Maria Del Ben, Roberto Cangemi, Francesco Barillà, Gregory Y.H. Lip & Francesco Violi. (2015) Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation. International Journal of Cardiology 201, pages 513-516.
Crossref
Crossref
Daniele Pastori, Pasquale Pignatelli, Francesco Angelico, Alessio Farcomeni, Maria Del Ben, Tommasa Vicario, Tommaso Bucci, Valeria Raparelli, Roberto Cangemi, Gaetano Tanzilli, Gregory Y.H. Lip & Francesco Violi. (2015) Incidence of Myocardial Infarction and Vascular Death in Elderly Patients With Atrial Fibrillation Taking Anticoagulants. Chest 147:6, pages 1644-1650.
Crossref
Crossref
Aaron Liew, Siavash Piran & James Douketis. (2015) New oral anticoagulants versus vitamin K antagonists for treatment of acute venous thromboembolism: do they really increase the incidence of myocardial infarction?. Internal and Emergency Medicine 10:4, pages 493-498.
Crossref
Crossref
Daniele Pontillo & Nicolino Patruno. (2015) Pitfalls of the interpretation of myocardial infarction data in patients on dabigatran treatment. Journal of Cardiovascular Medicine 16:2, pages 142.
Crossref
Crossref
Bruce L. Davidson. (2015) The Association of Direct Thrombin Inhibitor Anticoagulants With Cardiac Thromboses. Chest 147:1, pages 21-24.
Crossref
Crossref
Amadea M. Martischnig, Julinda Mehilli, Janina Pollak, Tobias Petzold, Anette K. Fiedler, Katharina Mayer, Stefanie Schulz-Schüpke, Dirk Sibbing, Steffen Massberg, Adnan Kastrati & Nikolaus Sarafoff. (2015) Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials). BioMed Research International 2015, pages 1-10.
Crossref
Crossref
Gregory Y.H. Lip, Stephan Windecker, Kurt Huber, Paulus Kirchhof, Francisco Marin, Jurriën M. Ten Berg, Karl Georg Haeusler, Giuseppe Boriani, Davide Capodanno, Martine Gilard, Uwe Zeymer, Deirdre Lane, Robert F. Storey, Hector Bueno, Jean-Philippe Collet, Laurent Fauchier, Sigrun Halvorsen, Maddalena Lettino, Joao Morais, Christian Mueller, Tatjana S. Potpara, Lars Hvilsted Rasmussen, Andrea Rubboli, Juan Tamargo, Marco Valgimigli & Jose L. Zamorano. (2014) Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). European Heart Journal 35:45, pages 3155-3179.
Crossref
Crossref
Sarah L. Greig & Kate McKeage. (2014) Dabigatran Etexilate: A Review of Its Use in the Treatment of Acute Venous Thromboembolism and Prevention of Venous Thromboembolism Recurrence. Drugs 74:15, pages 1785-1800.
Crossref
Crossref
Francesco Summaria, Enrico Romagnoli, Marina Mustilli, Roberto Patrizi & Adolfo Pagnanelli. (2014) Primary PCI in dabigatran-treated patient: is transradial approach and bivalirudin infusion a safe and effective therapeutic option?. Internal and Emergency Medicine 9:6, pages 695-698.
Crossref
Crossref
Sascha Meyer dos Santos & Sebastian Harder. (2014) Benefit–Risk Assessment of Dabigatran in the Treatment of Stroke Prevention in Non-Valvular Atrial Fibrillation. Drug Safety 37:5, pages 295-307.
Crossref
Crossref
Flemming Skjøth, Torben Larsen, Lars Rasmussen & Gregory Y. H. Lip. (2017) Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. Thrombosis and Haemostasis 111:05, pages 981-988.
Crossref
Crossref